Clinical trials: Relapsed
Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia
The purpose of this single-arm, open label, phase-II trial, is to determine whether the association of Midostaurin to standard induction, consolidation therapy and in maintenance therapy as single agent, is effective in decrease…
- Trial name
- AML FLT3 (NCT03686345)
- Testing
- Midostaurin
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Niguarda Hospital
Nephrotic Syndrome in Children
Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome
This study investigated the combined impact of rituximab and targeted nursing care versus tacrolimus and targeted nursing care on efficacy, quality of life, adverse reactions, and recurrence rate in children with challenging…
- Trial name
- NCT07049172
- Testing
- Rituximab, Targeted Nursing Care, Baseline Glucocorticoid Therapy
- Where
- China
- Volunteers
- 91 people
- Sponsor
- Wuhan Children's Hospital
B Cell Lymphoma, Multiple Mieloma
Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma
CARBIOM is a single-centre, non-randomized interventional study involving additional biological sampling with minimal risks and constraints.
- Trial name
- CARBIOM (NCT07852377)
- Testing
- Biological sample collection and immunomonitoring
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Henri Becquerel
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT07082686
- Testing
- ICP-248
- Where
- 29 sites in China
- Volunteers
- 75 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed Refractory Multiple Myeloma (RRMM)
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of…
- Trial name
- NCT07831122
- Testing
- Belamaf, Cevostamab, Pomalidomide
- Where
- 7 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Canadian Myeloma Research Group
DLBCL - Diffuse Large B Cell Lymphoma
Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient…
- Trial name
- NCT06299553
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Incyte Biosciences Italy S.r.l
Relapse Multiple Myeloma
Melflufen for Elderly Patients With Relapsed Myeloma
This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse. Thirty elderly patients at second or subsequent relapse.
- Trial name
- NCT06682637
- Testing
- Melflufen, Dexamethasone
- Where
- 10 sites in Italy
- Sponsor
- Fondazione EMN Italy Onlus
B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).
- Trial name
- NCT03671460
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tianjin Mycure Medical Technology Co., Ltd
Neuroblastoma
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in combination with chemotherapy…
- Trial name
- NCT03107988
- Testing
- Lorlatinib, Cyclophosphamide, Topotecan
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 65 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Aplastic Anemia
Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.
The study is a phase I/II trial designed to establish the safety and efficacy of intravenous administration of bone marrow derived mesenchymal stem cells from related donor to patients with relapsed/refractory aplastic anemia.
- Trial name
- MSC (NCT01305694)
- Testing
- bone marrow derived mesenchymal stem cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
This phase II trial tests how well the combination of epcoritamab and lenalidomide work in treating patients with immunodeficiency-related large B-cell lymphoma that does not respond to treatment (refractory) or that has come…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT06723457
- Testing
- Biospecimen Collection, Computed Tomography, Epcoritamab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Reem Karmali
Hematological Malignancy, Lymphoma
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
This is a phase Ia/Ib, first-in-Human, open-Label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy…
- Trial name
- NCT05293912
- Testing
- SG2501
- Where
- 8 sites in United States
- Volunteers
- 2 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
EBV Associated Lymphoid Neoplasms
GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
This is a Phase 1/Phase 2 open-label, single-arm clinical study of GP350 CAR-T for Relapse/Refractory and Epstein-Barr virus infection associated lymphoid neoplasms.
- Trial name
- ANXIN-02 (NCT07306156)
- Testing
- GP350 CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhimin Zhai
Leukemia, Myeloid
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The purpose of this study is to evaluate the safety and efficiency of high dose allogeneic mismatched hematopoietic stem cells infusions after normal chemotherapy in patients with relapsed/refractory acute myeloid leukemia（AML）.
- Trial name
- NCT03080922
- Testing
- hematopoietic stem cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Eye Cancer, Retinoblastoma
A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
While 95% of patients with retinoblastoma can be cured nowadays, treatment of relapse remains challenging, ending often in enucleation and/or radiotherapy.
- Trial name
- EuRbG2018 (NCT04455139)
- Testing
- Topotecan, Melphalan
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Prof. Beck Popovic Maja
Recurrent Plasma Cell Myeloma, T(11;14)
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
This phase I trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back.
- Trial name
- NCT03399539
- Testing
- Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
Central Nervous System Neoplasm, Solid Neoplasm
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
This phase I trial studies the side effects and best dose of trebananib in treating patients with solid tumors that has returned after a period of improvement or does not respond to treatment, including central nervous system…
- Trial name
- NCT01538095
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 22 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Ovarian Cancer
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .
- Trial name
- NCT06081595
- Testing
- Fluzoparib, Apatinib
- Volunteers
- 54 people
- Sponsor
- Jin Li
Multiple Myeloma
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
- Trial name
- MAGNETISMM17 (NCT05462639)
- Testing
- Elranatamab (PF-06863135)
- Where
- 36 sites in United States, Canada
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.